In vitro studies on the relationship between the anti-inflammatory activity of Physalis peruviana extracts and the phagocytic process

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 1, 2010, Pages 63-73

  Martínez, Willington ^a   Ospina, Luis Fernando ^a   Granados, Diana ^a,b   Delgado, Gabriela ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Foundation Institute of Immunology of Colombia   (Colombia)

Author keywords

Immunomodulation; Inflammation; J774 cells; Leishmania phagocytosis model; Phagocytosis; Physalis peruviana

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; ETHER; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN; PHYSALIS PERUVIANA EP1 EXTRACT; PHYSALIS PERUVIANA EP2 EXTRACT; PHYSALIS PERUVIANA EP3 EXTRACT; PHYSALIS PERUVIANA ET1 EXTRACT; PHYSALIS PERUVIANA ET2 EXTRACT; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; FRACTIONATION; IMMUNOMODULATION; IMMUNOTOXICITY; IN VITRO STUDY; INFLAMMATION; INTERNALIZATION; LEISHMANIA PANAMENSIS; MACROPHAGE; MEDICINAL PLANT; MICROORGANISM; MOUSE; NONHUMAN; PARASITE CULTIVATION; PHAGOCYTOSIS; PHYSALIS PERUVIANA; PRIORITY JOURNAL; PROTOZOAL INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; LEISHMANIA; MACROPHAGES; MICE; PHAGOCYTOSIS; PHYSALIS; PLANT EXTRACTS;

LEISHMANIA PANAMENSIS; MURINAE; PHYSALIS PERUVIANA; SOLANACEAE;

EID: 77249143982     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970903143957     Document Type: Article

References (24)

1. Rang H, Dale MM, Ritter JM, Moore PK. Pharmacology. Churchill Livingstone, Edinburg, 2003.
2. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723.
3. Murphy K, Travers, P, Walport M. Janewaýs immunobiology. Gardland Science, Newyork, 2007.
4. Karsh J. Anti-inflammatory drugs: what is safe? Can Med Assoc J. 2006,175 449.
5. Wu S., Ng LT, Lin DL, et al. Physalis peruviana extract induces apoptosis in human Hep G2 cells through CD95/CD95L system and the mitochondrial signaling transduction pathway. Cancer Lett 2004;215:199-208.
6. Wu SJ, Ng LT, Huang YM, et al. Antioxidant activities of Physalis peruviana. Biological PharmaceutBull 2005;28:963-966.
7. Wu SJ, Tsai, JY, Chang SP, et al. Supercritical carbon dioxide extract exhibits enhanced antioxidant and anti-inflammatory activities of Physalis peruviana. J Ethnopharmacol 2006;108:407-413.
8. Franco LA, Matiz GE, Calle J, et al. Antiinflammatory activity of extracts and fractions obtained from Physalis peruviana L. calyces. Biomedica 2007;27:110-115.
9. de Fries R, Mitsuhashi M. Quantification of mitogen induced human lymphocyte proliferation: comparison of alamarBlue assay to 3H-thymidine incorporation assay. J Clin Lab Anal 1995;9 (2):89-95.
10. Osorio E, Arango GJ, Jimenez N, et al. Antiprotozoal and cytotoxic activities in vitro of Colombian Annonaceae. J Ethnopharmacol 2007;111(3):630-635.
11. Raynaud-Le Grandic S, Fourneau C, Laurens A, et al. In vitro antileishmanial activity of acetogenins from Annonaceae. Biomed Pharmacother2004;58(6-7):388-392.
12. Saravia NG, Nicholls RS Leishmaniasis: a public health challenge that demands concerted effort and will (editorial). Biomedica 2006;26(Suppl 1):7-9.
13. Jones DE, Elloso MM, Scott P. Host susceptibility factors to cutaneous leishmaniasis. Front Biosci 1998;3:1171-1180.
14. Aguilar-Torrentera F, Carlier, Y. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev. Latinoam. Microbiol 2001;43:35-142.
15. Teixeira MJ, Teixeira CR, Andrade BB, et al. Chemokines in host-parasite interactions in leishmaniasis. Trends Parasitol 2006;22:32-40.
16. Bretscher PA, Ogunremi O, Menon J.N Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring Inst Mitt 1997; (98):153-159.
17. Crisby, M. Modulation of the inflammatory process by statins. Drug Today (Barc) 2003;39:137-143.
18. Allison AC, Cacabelos R, Lombardi VR, et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(7):1341-1357.
19. Bultzingslowen I, Jontell M. Macrophages, dendritic cells and T lymphocytes in rat buccal mucosa and dental pulp following 5-fluorouracil treatment. Eur J Oral Sci 1999;107(3):194-201.
20. Vasquez RE, Soong L. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect Immun 2006;74(12):6769-6777.
21. Dey. , Majumder N, Bhattacharyya Majumdar S, et al. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Scand J Immunol 2007;66(6):671-683.
22. Brandonisio O, Panaro MA, Fumarola I., et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002;2 (3):125-129.
23. Schulte A, Ruehl-Fehlert C. Regulatory aspects of immunotoxicology. Exp Toxicol Pathol 2006;57(5-6):385-389.
24. Spanhaak S. The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity? Exp Toxicol Pathol 2006;57:373-376.